Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Free Cash Flow (2016 - 2022)

Edesa Biotech's Free Cash Flow history spans 10 years, with the latest figure at -$5.6 million for Q3 2022.

  • For Q3 2022, Free Cash Flow fell 1490.52% year-over-year to -$5.6 million; the TTM value through Sep 2022 reached -$12.3 million, up 10.14%, while the annual FY2025 figure was -$7.3 million, 49.28% down from the prior year.
  • Free Cash Flow for Q3 2022 was -$5.6 million at Edesa Biotech, down from -$3.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$353857.0 in Q3 2021 and bottomed at -$7.2 million in Q1 2021.
  • The 5-year median for Free Cash Flow is -$1.6 million (2018), against an average of -$2.3 million.
  • The largest YoY upside for Free Cash Flow was 94.18% in 2022 against a maximum downside of 1490.52% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$388012.0 in 2018, then tumbled by 103.53% to -$789712.0 in 2019, then plummeted by 281.36% to -$3.0 million in 2020, then dropped by 6.61% to -$3.2 million in 2021, then crashed by 75.29% to -$5.6 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Free Cash Flow are -$5.6 million (Q3 2022), -$3.0 million (Q2 2022), and -$417853.0 (Q1 2022).